BEAM THERAPEUTICS REPORTS INITIAL CLINICAL DATA FROM PHASE 1/2 TRIAL OF BEAM-301, DEMONSTRATING PROOF OF CONCEPT FOR GENETIC CORRECTION IN GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA) AT ESGCT 33RD ANNUAL CONGRESS

Reuters · 10/27 11:02

Please log in to view news